We Demand More:

The treatments currently available for cancer are just not good enough.
Most treatments on the market make cancer patients sick before they can get better.

Technology:

We have an innovative solution that has been overlooked. Together with our investors and partners, our “Interceptor” approach will revolutionize the direction of cancer treatment, with safety in mind.

Immunotherapy:

Immunotherapies have transformed cancer R&D. Pharmaceutical companies are actively seeking early-stage drugs with unique MOA for stand-alone or combination therapies. Oncology immunotherapy sales are steadily growing and predicted to generate $111B per year by 2020. Our treatment provides an opportunity in the immunotherapy space for investors and/or partners.